Citadel Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$164M Buy
1,551,900
+425,213
+38% +$37.6M 0.12% 545
2025
Q4
$98.4M Buy
1,126,687
+888,806
+374% +$72.7M 0.07% 878
2025
Q3
$15.8M Buy
237,881
+210,680
+775% +$12M 0.01% 2624
2025
Q2
$1.5M Sell
27,201
-126,866
-82% -$6.09M ﹤0.01% 6252
2025
Q1
$7.45M Sell
154,067
-10,079
-6% -$422K 0.01% 3272
2024
Q4
$6.34M Buy
164,146
+159,116
+3,163% +$6.94M 0.01% 3591
2024
Q3
$226K Buy
+5,030
New +$203K ﹤0.01% 9894
2024
Q2
Sell
-45,616
Closed -$1.34M 15236
2024
Q1
$1.32M Sell
45,616
-2,248
-5% -$61.2K ﹤0.01% 6357
2023
Q4
$1.1M Sell
47,864
-2,932
-6% -$51.3K ﹤0.01% 6484
2023
Q3
$847K Sell
50,796
-498,198
-91% -$9.67M ﹤0.01% 6923
2023
Q2
$15.2M Sell
548,994
-615,686
-53% -$15.4M 0.02% 2167
2023
Q1
$26.8M Sell
1,164,680
-1,190,634
-51% -$20M 0.03% 1637
2022
Q4
$25.7M Buy
2,355,314
+1,488,927
+172% +$12.6M 0.03% 1701
2022
Q3
$7.3M Buy
866,387
+792,258
+1,069% +$7.5M 0.01% 3243
2022
Q2
$586K Sell
74,129
-112,695
-60% -$1.36M ﹤0.01% 8288
2022
Q1
$4.42M Buy
186,824
+151,276
+426% +$4.26M 0.01% 4417
2021
Q4
$1.22M Sell
35,548
-83,156
-70% -$2.63M ﹤0.01% 7461
2021
Q3
$2.1M Sell
118,704
-284,504
-71% -$12.1M ﹤0.01% 6229
2021
Q2
$18.1M Buy
403,208
+204,990
+103% +$6.77M 0.02% 2208
2021
Q1
$5.13M Sell
198,218
-142,604
-42% -$3.61M 0.01% 4202
2020
Q4
$6.87M Buy
+340,822
New +$7.34M 0.01% 3146
2020
Q2
Sell
-469,212
Closed -$3.31M 10425
2020
Q1
$3.31M Buy
469,212
+10,119
+2% +$75.8K 0.01% 3306
2019
Q4
$3.24M Buy
459,093
+42,838
+10% +$425K ﹤0.01% 3678
2019
Q3
$5M Buy
416,255
+6,408
+2% +$80.8K 0.01% 3112
2019
Q2
$4.96M Buy
409,847
+46,120
+13% +$510K 0.01% 3095
2019
Q1
$4.57M Buy
363,727
+328,965
+946% +$2.9M 0.01% 3130
2018
Q4
$234K Sell
34,762
-995
-3% -$7.89K ﹤0.01% 7642
2018
Q3
$368K Sell
35,757
-95,644
-73% -$823K ﹤0.01% 7231
2018
Q2
$883K Buy
131,401
+82,204
+167% +$631K ﹤0.01% 5439
2018
Q1
$423K Buy
+49,197
New +$927K ﹤0.01% 6187

Other funds holding PTGX